Protalix BioTherapeutics Presents Data Supporting Potential for Less Frequent Dosing in Phase 2 RELEASE Study for Uncontrolled Gout

• The Company previously reported that higher single doses of PRX–115 lowered mean plasma uric acid for longer durations in participants with elevated plasma uric acid levels (ACR 2024)
• New individual patient data presented at ACR 2026 reinforce this finding and show the effect associated with PRX-115 plasma levels remaining measurable for up to 85 days
• The Company believes PRX-115 has best-in-class potential in uncontrolled gout, a high unmet need with top-line results from the Phase 2 RELEASE study expected in the second half of 2027

CARMIEL, Israel, Nov. 9, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced individual participant results from a pharmacokinetic (PK) and pharmacodynamic (PD) analysis of the higher-dose cohorts of its Phase 1 single ascending dose study of PRX-115, a plant cell–expressed recombinant PEGylated uricase in development for uncontrolled gout. The Company is presenting the analysis in a poster at the American College of Rheumatology (ACR) Convergence 2026 taking place in Orlando, Florida from November 6-11, 2026.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.